Extracellular matrix protein 1 (ECM1) is a potential biomarker in B-cell acute lymphoblastic leukemia

doi:10.21203/rs.3.rs-3134486/v1

Download PDF

Research Article

Extracellular matrix protein 1 (ECM1) is a potential biomarker in B-cell acute lymphoblastic leukemia

https://doi.org/10.21203/rs.3.rs-3134486/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 28 Mar, 2024

Read the published version in Clinical and Experimental Medicine →

You are reading this latest preprint version

B-cell acute lymphoblastic leukemia (ALL) is characterized by the highly heterogeneity of pathogenic genetic background, and there are still approximately 30-40% of patients without clear molecular markers. To identify the dysregulated genes in B-cell ALL, we screened 30 newly diagnosed B-cell ALL patients and 10 donors by gene expression profiling chip. We found that ECM1 transcript level was abnormally elevated in newly diagnosed B-cell ALL and further verified in another 267 cases compared with donors (median, 124.57% vs. 7.14%, P<0.001). ROC analysis showed that the area under the curve of ECM1transcript level at diagnosis was 0.89 (P <0.001). Patients with BCR::ABL1and IKZF1 deletion show highest expression level (210.78%) compared with KMT2A rearrangement (39.48%) and TCF3::PBX1 rearrangement ones (30.02%) (all P <0.05). Also, the expression level of ECM1 was highly correlated with the clinical course, as 20 consecutive follow-up cases indicated. The 5-year OS of patients (non-KMT2A and non-TCF3::PBX1rearrangement) with high ECM1 transcript level was significantly worse than the lower ones (18.7% vs. 72.9%, P <0.001) and high ECM1transcript level was an independent risk factor for OS (HR=5.77 [1.75-19.06], P=0.004). After considering transplantation, high ECM1 transcript level was not an independent risk factor, although OS was still poor (low vs.high, 71.1% vs. 56.8%, P =0.038). Our findings suggested that ECM1may be a potential molecular marker for diagnosis, minimal residual disease (MRD) monitoring, and prognosis prediction of B-cell ALL.

Trial Registration

Trial Registration Registered in the Beijing Municipal Health Bureau Registration N 2007–1007 and in the Chinese Clinical Trial Registry [ChiCTR-OCH-10000940 and ChiCTR-OPC-14005546]; http://www.chictr.org.cn.

B-cell acute lymphoblastic leukemia

ECM1

diagnosis

MRD

prognosis

We found that the transcription level of ECM1 was significantly higher in newly diagnosed B-cell ALL patients than healthy donor. And the transcription level of ECM1 was related to different genetic backgrounds and disease course. Moreover, as an independent risk factor for OS, the poor survival in ones with high ECM1 transcription level could be improved by transplantation. Our findings suggested that ECM1 may be a potential molecular marker in B-cell ALL.

B-cell acute lymphoblastic leukemia (B-cell ALL) is a malignant clonal disease originating from lymphoid hematopoietic stem cells. It presents highly heterogeneous clinical manifestation, which is fundamentally the heterogeneity of pathogenic genetic background ¹. According to these studies, the heterogeneity may mainly attribute to the following two aspects: 1) Diverse recurrent somatic alterations. These alterations encompass aneuploidy, chromosomal rearrangements, DNA copy number alterations, and sequence mutations, referred to as primary genetic abnormalities to define distinct subtypes ². Recently, Gu et al. performed RNA sequencing in B-cell ALL and identify several novel driver events with different gene expression signature, subdividing the subtypes to as many as 23 ³. 2) Cooperating or secondary aberrations. Studd et al. found that additional mutation burden varied significantly across subtypes. Patients with intrachromosomal amplification of chromosome 21 (iAMP21) harbored the highest burden, and the KMT2A rearrangement (KMT2A-r) ones the lowest ⁴. Besides, under the selection pressure of treatment, additional aberrations would be lost, gained or enriched, termed as clonal evolution ⁵.

Advances in genetic testing methods have made it possible for us to fully understand the molecular regulatory network in B-cell ALL. Over the past decade, genomic analysis has revolutionized the cognition of researchers and clinicians on the biology of B-cell ALL⁶. For example, patients with high hyperdiploid ALL generally up-regulate gene expression on the gained chromosomes in dosage effect. However, Yang et al. found that CTCF, which regulates chromatin architecture, displayed low expression in these patients ⁷. Another important notion in B-cell ALL is “phenocopy”, which refers to the cases with alternative or unknown driver events show similar gene expression profile to the well characterized drivers ⁸. The best known is Ph-like ALL, which copies the signature of ones with BCR::ABL1⁹. Recently, more and more phenocopies were identified, including ETV6::RUNX1-like, KMT2A rearrangement-like, hyperdiploid like and so on^4,10,11. These findings improve the stratification of B-cell ALL and offer potential treatment strategies for these newly defined subgroups.

Here, to further unveil the aberrations in B-cell ALL, we used gene expression profiling chip in 30 newly diagnosed B-cell ALL patients and 10 donors. We found that extracellular matrix protein 1 (ECM1) was up-regulated in B-cell ALL. Our data suggested that ECM1 was a potential biomarker for diagnosis, minimal residual disease (MRD) monitoring and prognosis prediction of B-cell ALL.

Patients and treatments

In this study, we collected bone marrow samples and corresponding clinical data from newly diagnosed (N = 297), complete remission (CR, N = 41), relapsed (N = 42) B-cell ALL patients and healthy donors (N = 32), from March 2012 to December 2018 in Peking University People's Hospital. The diagnostic criteria for B-cell ALL refer to the 2016 WHO guidance. All patients received standard chemotherapy regimens. According to physician evaluation and patient conditions, consolidation therapy could be chemotherapy or allogeneic hematopoietic stem cell transplantation. Among them, BCR::ABL1 positive patients were treated with tyrosine kinase inhibitors. This study was approved by the Ethics Committee of Peking University People's Hospital in accordance with the Declaration of Helsinki. All patients signed informed consent.

Immunophenotype, MRD and cytogenetic analyses

Multi-parameter flow cytometry (MFC) was used to identified the immunophenotype at diagnosis. The antibody combinations could be referred to the previous report¹². MRD was assessed by MFC and molecular level. For MFC, leukemia-associated immunophenotypes were monitored. The sensitivity is 10^− 4 and level ≥ 10^− 4 was considered MFC-MRD positivity. For molecular level, fusion genes (BCR::ABL1, KMT2A-r, TCF3::PBX1, ETV6::RUNX1) and IKZF1 deletion were monitored if ones harbored any above-aberration. Expression level of WT1 was routinely monitored and > 0.60% was defined as positive. Cytogenetic analysis was done by standard G-banding and/or FISH¹³.

Gene expression microarray

Mononuclear cells were isolated from bone marrow samples by Ficoll-Hypaque density gradient centrifugation (Solarbio Technology, Beijing, China). RNA was extracted by Trizol® kits (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. A total of > 1ug RNA was used from each of the 30 newly diagnosed B-cell ALL patients and 10 donors for gene expression microarray.

Reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR)

Reverse transcription was performed as previously described¹⁴. Taqman-based qRT-PCR was performed by ABI PRISM® 7500 Fast Sequence Detection System (Applied Biosystem, Foster City, CA, USA)¹⁵. ABL1 was used as internal control. Primers and probes were shown as follows: ECM1, forward primer, 5’-CAAAGAGTTCTCACCAAGCATAAACA-3’; reverse primer, 5’-TCTGGAAATGGCAGGTCACA-3’; probe, 5’-FAM-TGGGCTGATCCACAACATGACTGCC-BHQ-3’. ABL1, forward primer, 5’-TGGAGATAACACTCTAAGCATAACTAAAGGT-3’; reverse primer, 5’-GATGTAGTTGCTTGGGACCCA-3’; probe, 5’-FAM-CCATTTTTGGTTTGGGCTTCACACCATT-TAMRA-3’.

GEO dataset validation

B-cell ALL dataset GSE34861 was retrieved from GEO database to analyze the basic information and prognosis of patients with different transcript level of ECM1, further verifying the clinical significance of ECM1 in B-cell ALL.

Statistical analysis

Statistical analysis was performed using SPSS 22.0 and Graphpad Prism 7.0. The normal distribution data was shown as mean ± standard deviation, and compared by Student-t test. Non-normal distribution data were represented by median and full range, and compared by Mann-Whitney U test. Categorized variables were compared by chi-square test or Fisher's exact test. Correlation of two variables was analyzed by Spearman correlation test. The receiver operator characteristic (ROC) curve was used to evaluate the diagnostic sensitivity and specificity of ECM1. Overall survival (OS) is defined as the patient's survival time from initial diagnosis to death from any cause, last contact, or December 31st, 2020. Kaplan Meier method was used to estimate OS and log rank test was performed to compare. Variables with P < 0.1 were enrolled in the multivariate analysis using a Cox proportional risk regression model. P < 0.05 is considered statistically significant.

Dysregulated gene expression in B-cell ALL

A total of 30 newly diagnosed B-cell ALL and 10 normal donors were enrolled for gene expression microarray. Patient characteristics were shown in Supplementary Table 1. There were 19 males and the median age was 32.5 years old. Most of them were common-B ALL (N = 22, 73.3%) and the most common cytogenetics abnormality is t(9;22)(q34;q11). Correspondingly, BCR::ABL1 fusion accounted for nearly half of the patients (N = 14, 46.7%). IKZF1 deletion (N = 14, 46.7%) often concurred with BCR::ABL1, and 8 ones both harbored BCR::ABL1 fusion and IKZF1 deletion (double-positive). There were 10 double-negative cases, while IKZF1-positive and BCR::ABL1-positive were 6 cases each. Five cases had KMT2A-r fusion, one had TCF3::PBX1 fusion and none of them had ETV6::RUNX1 fusion. As for donors, there were 6 males and the median age was 43 years old.

We firstly subdivided B-cell ALL patients into 4 subgroups according to the BCR::ABL1 and IKZF1 status to unveiled the dysregulated genes in different background. As shown in Supplementary Fig. 1 and Supplementary Table 2, the most significant difference was seen in double-positive and double-negative group. In the double-negative group, the up-regulated genes were 538 more than that in the double-positive group, but the down-regulated genes were significantly reduced, reaching 1744.

ECM1 had high transcription level in B-cell ALL

We found that the two transcripts (NM_004425, NM_022664) of ECM1 were both highly transcribed in the four subgroups (Supplementary Table 3), indicating that the abnormal expression of ECM1 may have universal significance in B-cell ALL. To elucidate the possibility of ECM1 as a potential molecular marker in B-cell ALL, we further verified the transcription level of ECM1 in samples from newly diagnosed (N = 267), complete remission (CR, N = 41) and relapsed (N = 42) B-cell ALL, as well as 22 healthy donors. Our data showed that the highest level of ECM1 transcription was found in newly diagnosed B-cell ALL patients, with a median of 124.57% (0.79-3519.50%), significantly higher than in CR patients (median, 3.95% [1.50-11.22%], P < 0.001) and donors (median, 7.14% [1.54–10.27%], P < 0.001). Transcription level elevated again in relapsed patients, with a median of 107.62% (1.19-1142.81%), and was significantly higher than in CR patients (P < 0.001) and donors (P < 0.001) (Fig. 1A). We also detected ECM1 transcription level in AML, including 15 newly diagnosed and 13 CR samples. The median transcription level of newly diagnosed AML was 6.88% (1.50-35.76%), and the median in CR was 3.21% (1.43–5.36%). There was no significant difference in ECM1 transcription levels between newly diagnosed AML and normal donors (P = 0.551). ROC analysis of ECM1 transcription level in newly diagnosed B-cell ALL patients showed that the area under the curve was 0.89 (95% confidence interval, 0.85–0.93; P < 0.001) (Fig. 1B). The maximum Youden index is 0.846, corresponding to an ECM1 transcription level of 10.28%. Taking 10.28% as the diagnostic threshold, the sensitivity and specificity for diagnosis was 84.6% and 100%, respectively. We further compared the diagnostic performance of ECM1 with WT1 in B-cell ALL. In 265 patients who were tested for both ECM1 and WT1, the overall false negative rate of ECM1 in diagnosing B-cell ALL was 15.1%, while the false negative rate of WT1 was 34.3%. The overall false negative rate of the two genes was 4.2% (Supplementary Table 4). Therefore, we suggested that ECM1 is more sensitive than WT1 in diagnosing B-cell ALL, and these two genes could complement each other.

We also compared the transcription levels of ECM1 among different subgroups (Fig. 2A-B). Among them, patients with KMT2A-r, TCF3::PBX1, and ETV6::RUNX1 were further grouped independently. Multiple comparison showed that there was no significant difference in transcription levels among the double-negative (median, 93.50% [0.83 ~ 3519.50%]), IKZF1-positive (median, 97.77% [0.79 ~ 1397.76%]), and the BCR::ABL1-positive subgroups (median, 141.22% [11.33 ~ 754.35%]) (both P > 0.05). Double-positive group showed the highest transcription level, with a median level of 210.78% (45.30 ~ 714.05%). Patients with KMT2A-r and TCF3::PBX1 had the lowest transcription levels, with a median of 39.48% (6.28 ~ 165.32%) and 30.02% (1.78 ~ 82.54%), respectively. However, the transcription level of patients with ETV6::RUNX1 was not low (median, 104.87% [50.84 ~ 424.05%]). The transcription level in the double-positive ones was significantly higher than that in the double-negative (P = 0.001), the IKZF1-positive (P = 0.005), KMT2A-r (P < 0.001), and TCF3::PBX1 ones (P < 0.001). As for immunophenotypes, Common-B ALL had the highest transcription level (median, 151.53% [0.79-3519.50%]), significantly higher than that in the Pre-B ALL (median, 12.45% [1.54-1373.54%]; P < 0.001). Transcription level in Pro-B ALL was also not high (median, 66.48% [0.85-1210.48%]; P = 0.053). We further investigated the diagnostic performance of ECM1 in patients except for KMT2A-r, TCF3::PBX1, and ETV6::RUNX1 rearrangements (Fig. 2C-F). In the double-negative group, the area under the curve was 0.82 (0.74–0.89; P < 0.001), slightly lower than that in the IKZF1-positive group (0.84 [0.76–0.93]; P < 0.001). However, in BCR::ABL1-positive and double-positive groups, the area under the curve was 1 (P < 0.001).

ECM1 had a good MRD monitoring performance

We further evaluate the value of ECM1 transcription level for MRD monitoring. In 20 consecutive follow-up cases, it was found that ECM1 transcriptional level down-regulated after achieving CR, but up-regulated at the time of relapse (Fig. 3A). We further monitored MRD of 5 long-term follow-up cases and compared ECM1 detection with other MRD monitoring techniques (morphology, flow cytometry, other genes in qRT-PCR) (Fig. 3B-F). All patients showed high ECM1 transcription level at diagnosis. Patients with long-term CR also maintained low transcription level of ECM1 (patients 1, 4, and 5), while refractory or relapse patients maintained high transcription level (patient 3). Relapsed patients after transplantation also showed elevated ECM1 transcription level (patients 1, 5).

As for morphology, the ECM1 transcription level was basically consistent with the blast at most bone marrow aspirations. In some patients, ECM1 transcription level detection was superior to morphology. For patient 2, after induction (the 2nd bone marrow aspiration), the morphology showed CR, but MFC and genes (BCR::ABL1, IKZF1) did not achieve, as well as ECM1 transcription level. Patient 4 relapsed during the 4th and 5th aspirations, and the sensitivity of ECM1 was superior to morphology. Molecular relapse occurred during the 12th and 13th aspirations, with an increase in ECM1 transcription level, but morphological relapse was at the 14th aspiration. Patients 1, 2, 3, and 5 provided follow-up MFC information. In patients with MFC-MRD, the transcription level of ECM1 was highly consistent with the MFC, especially in the relapsed samples. In terms of other genes, the transcription level of BCR::ABL1 (patients 2 and 4) and KMT2A-r (patient 3) showed good parallelism with ECM1 in disease course monitoring. Patient 2 also had IKZF1 deletion. The dynamics of IKZF1 deletion level and ECM1 transcription level was basically consistent. Patients 1, 3, and 5 provided WT1 follow-up information. The dynamics of WT1 transcription level was basically consistent with ECM1. Like other intramedullary MRD indicators, due to the fact that two patients with extramedullary recurrence (patients 1 and 5) did not suffer intramedullary relapse simultaneously, the transcription level of ECM1 did not indicate the status of extramedullary relapse well.

High ECM1 transcription level indicated worse OS

We divided 177 B-cell ALL patients with prognostic information into a high transcription level group (N = 86) and a low transcription level group (N = 91) based on the median transcription level of ECM1 (124.57%) (Table 1). In the high transcriptional level group, patients presented high-risk clinical features, such as older age (high transcriptional level group vs. low transcriptional level group, 35y vs. 29y, P = 0.008), high positive rate of MFC-MRD (≥ 0.01%) after induction (7 patients without MFC-MRD information) (64% vs. 43%, P = 0.005), high positive rate of MFC-MRD after 1 course of consolidation chemotherapy (18 patients without MFC-MRD information) (46% vs. 27%, P = 0.010) and after 2 courses of consolidation chemotherapy (33 patients without MFC-MRD information) (43% vs. 22%, P = 0.008). In terms of immunophenotype, patients with high transcriptional level were more likely Common-B ALL (P = 0.002). This result was consistent with the molecular genetics classification, because KMT2A-r is more common in the Pro-B ALL, while TCF3::PBX1 rearrangement is more common in the Pre-B ALL. The distribution of BCR::ABL1 and IKZF1 between the high and low transcription level groups was consistent with the above results. Patients with high transcriptional level were more likely to have BCR::ABL1 and IKZF1 deletion mutations (P < 0.05). There were no significant difference between the two groups in terms of gender, white blood cell count, hemoglobin concentration, platelet count, and treatment regimen (all P > 0.05).

Table 1

**Characteristics of 177 B-cell ALL patients**
Variables	ECM1 high (N = 86)	ECM1 low (N = 91)	P-value
Sex, N (%)
Male	45 (52%)	38 (42%)	0.159
Age, y
Median (range)	35 (14 ~ 71)	29 (14 ~ 67)	0.008
WBC, ×10⁹/L
Median (range)	17.1 (0.8 ~ 337.6)	14.1 (1.0 ~ 358.0)	0.896
Hemoglobin, g/L
Mean ± SD	93.9 ± 29.7	90.3 ± 25.9	0.389
Platelets, ×10⁹/L
Median (range)	44 (3 ~ 377)	57 (3 ~ 352)	0.148
Immunophenotype, N(%)			0.002
Common-B	73 (87)	60 (66)
Pro-B	9 (11)	18 (20)
Pre-B	2 (2)	13 (14)
Molecular/Cytogenetics, N(%)
BCR::ABL1	39 (45)	15 (16)	< 0.001
IKZF1 deletion	54 (63)	34 (37)	0.001
KMT2A-r	0	8 (9)	0.007
TCF3::PBX1	0	9 (10)	0.003
MRD ≥ 0.01%, N(%)
Induction	52 (64)	38 (43)	0.005
1st course consolidation	37 (46)	21 (27)	0.010
2nd course consolidation	31 (43)	16 (22)	0.008
Treatment, N(%)
Transplantation	60 (70)	70 (77)	0.281

The specific decreased ECM1 transcription level in KMT2A-r (N = 8) and TCF3::PBX1 (N = 9) patients suggested that the mechanism of ECM1 in these two subtypes may be different from that of non-KMT2A-r and non-TCF3::PBX1 patients. So, subsequent prognostic analysis did not include these patients. In the case of transplantation as censored event, the 5-year OS of patients with high ECM1 transcription level was significantly lower than patients with low transcription level (low vs. high, 72.9% vs. 18.7%, P < 0.001) (Fig. 4A). When transplantation was not treated as censored event, high transcription level of ECM1 still had a worse 5-year OS (low vs. high, 71.1% vs. 56.8%, P = 0.038) (Fig. 4B). Six factors with P < 0.1, including ECM1 transcription level (high vs. low), age (≥ vs. <35 years old), white blood cell (WBC, ≥ vs.<30 ×10⁹/L), BCR::ABL1 (positive vs. negative), IKZF1 deletion (positive vs. negative), and MFC-MRD after induction (positive vs. negative), were enrolled in the multivariate analysis (transplantation as censored event). Only high ECM1 transcription level, high WBC count, and positive MFC-MRD after induction were independent risk factors for OS (Supplementary Table 5). When transplantation was not considered as censored event, a total of four factors, including ECM1 transcription level, age, BCR::ABL1, and transplantation (yes vs. no), were enrolled in the multivariate analysis. Only BCR::ABL1 was an independent risk factor for OS, while receiving transplantation was an independent protective factor (Supplementary Table 6).

We further validated the clinical significance of ECM1 in patients by a B-cell ALL dataset GSE34861 from the GEO database, with a total of 191 patients. Samples in this database were obtained from bone marrow and peripheral blood. For greater comparability with our samples, we only enrolled 91 patients with samples obtained from bone marrow. The median transcription level of ECM1 in these patients was 14.58 (9.22–15.57). According to the median transcriptional level, there were 45 cases in the low transcription level group and 46 in the high. The comparison of clinical information between the two groups was basically consistent with our patients (Supplementary Table 7). Pro-B and Pre-B were still mainly seen in the low transcription level group. BCR::ABL1 mostly occurred in the high transcription level group, while KMT2A-r and TCF3::PBX1 were still only found in the low transcription level group. A total of 74 patients were enrolled in the OS analysis (1 patient without follow-up information and 16 patients with KMT2A-r or TCF3::PBX1 were excluded). Transplantation was not treated as censored event due to the lack of transplantation information in the dataset. Similar to Fig. 4B, patients with high ECM1 transcription level still had a poor prognosis (37.4% vs. 10.6%, P = 0.059) (Supplementary Fig. 2).

We further explored the potential mechanism by which high ECM1 transcription levels affected the prognosis of B-cell ALL. KEGG enrichment analysis of differentially expressed genes was performed in B-cell ALL patients with high ECM1 transcription level. We found 3 pathways with the highest enrichment score were involved in the regulation of cell migration, including leukocyte transendothelial migration, adherens junction and regulation of actin cytoskeleton (Fig. 5). These results suggested that ECM1 may affect the invasion and metastasis of tumor cells. In the leukocyte transendothelial migration pathway, the genes that contribute primarily to enrichment score were CD99, ACTN1, and CTNND1 (Supplementary Table 8).

In this study, we found that ECM1 was highly transcribed in B-cell ALL patients, which indicated ECM1 was a potential biomarker for B-cell ALL. Under the physiological conditions, ECM1 participated in the formation of extracellular matrix, cell adhesion, signal transduction, and tissue differentiation and maturation¹⁶. Therefore, the abnormality of this gene would cause complex pathological changes. It has been reported that ECM1 was over-expressed in many solid tumors, such as breast cancer, thyroid cancer, cholangiocarcinoma, lung cancer, bladder cancer, ovarian cancer, colorectal cancer, and was related to chemo-resistance, tumor invasion, metastasis and poor prognosis^17–26. Other studies also found that ECM1 was down-regulated in some tumors, such as esophageal cancer and prostate cancer, as a tumor suppressor^27,28. The above research suggests that ECM1 may have distinguish mechanisms in different cancers. In recent years, it has been found that mutated p53 protein can cooperate with Notch1 to promote ECM1 expression by relieving the promoter inhibition of ECM1, leading to T-ALL²⁹. However, ECM1 has not yet been reported in B-cell ALL. In AML, ECM1 was transcribed at a level comparable to that of the donor, which indicated a specific role of ECM1 in ALL. ROC analysis indicated a good diagnostic performance of ECM1 in B-cell ALL, and in combination with WT1 could further improve the sensitivity. These results indicated that ECM1 could serve as a good auxiliary diagnostic biomarker for B-cell ALL.

Interestingly, we found that ECM1 showed significantly different transcription level in different genetic background, further confirming the heterogeneity of B-cell ALL with different driver events. The transcription level of ECM1 in BCR::ABL1 positive patients was higher than that in BCR::ABL1 negative, and the highest level was found in BCR::ABL1 and IKZF1 deletion double-positive patients. However, in BCR::ABL1 negative subjects, IKZF1 deletion had no significant correlation with ECM1 transcription level. Diagnostic test evaluation suggested that the sensitivity and specificity of ECM1 in the diagnosis of B-cell ALL in patients with BCR::ABL1 reached 100%. However, due to the sample size of healthy donors, the diagnostic performance of ECM1 for BCR::ABL1 subjects and whether there is a synergistic effect with IKZF1 still need to be further explored. However, in patients with KMT2A-r and TCF3::PBX1 rearrangement, the transcription level of ECM1 decreased significantly, although still higher than the donors. Transcription level in ETV6::RUNX1 patients was comparable to those in BCR::ABL1 negative ones, but the number of ETV6::RUNX1 cases was too small to draw a solid conclusion.

Detecting MRD is an important disease course monitoring and risk stratification method in the clinical treatment of B-cell ALL, with the advantage of being applicable to over 90% of patients⁶. At present, MRD detection is mainly performed in clinical practice by combining techniques such as flow cytometry and PCR. Stow et al.³⁰ showed that even if the MRD detected by flow cytometry was less than 0.01%, some patients still had a higher risk of relapse. Therefore, identify the deeper MRD level is the hot spot for MRD monitoring. Although the second-generation sequencing technology has a higher sensitivity (at least 10^− 6) than the aforementioned detection methods, further clinical application is limited due to its high cost. Overall, qRT-PCR is currently one of the most cost-effective and sensitive (over 10^− 5) MRD monitoring methods. IGH rearrangement is a widely used target in qRT-PCR MRD monitoring in B-cell ALL patients. However, only approximately 50–75% of B-cell ALL patients have typical IGH rearrangement³¹.

Therefore, development of new molecular markers based on qRT-PCR MRD detection methods is crucial for assisting clinical course monitoring and prognosis prediction. We found that the dynamic transcription level of ECM1 was consistent with the clinical course of B-cell ALL. Compared with other MRD detection techniques, ECM1 transcription level detection was not inferior than morphology, flow cytometry, and quantitative detection of other genes. These results suggest that ECM1 is a good MRD monitoring indicator. Someone, with low transcription level of ECM1 need to be evaluated with other techniques, especially in ones with KMT2A-r or TCF3::PBX1.

Finally, we found that in patients with transplantation as censored event, high ECM1 transcription level had poor prognosis and was an independent risk factor for OS. The poor outcome may result from ECM1 properties of promoting invasion and metastasis. CD99 contributed mainly to the cell migration. Recent study reported that CD99 also showed poor prognosis in B-cell ALL³². Surprisingly, the transcription level of CD99 among different subgroups in B-cell ALL was quite similar to that of ECM1. Patients with BCR::ABL1 has high CD99 transcription level and ones with KMT2A-r and TCF3::PBX1 had the lowest. Interestingly, patients with CRLF2 rearrangements, one of the types of Ph-like ALL, showed highest CD99 transcription level. These results indicated a closely relationship between BCR::ABL1 signature and CD99 transcription. CD99 was a target of MMP9³³, a gene reducing cell migration. Reports also demonstrated that ECM1 could activate or inhibit the activity of MMP9 in different cancers and genodermatosis^21,34,35. Collectively, ECM1 may interact with MMP9 and CD99 directly or indirectly to promote cell migration in B-cell ALL, especially ones with BCR::ABL1.

However, when considering transplantation, high transcription level of ECM1 was no longer an independent risk factor. The poor prognosis caused by high transcription level of ECM1 could be improved by transplantation. Therefore, patients with high transcription level of ECM1 should be considered as high risk, and should be closely monitored and given a transplantation as much as possible.

In summary, we have identified ECM1 as a new biomarker for B-cell ALL. Due to the correlation between its transcription level and genetic background, the high transcription level of ECM1 is more likely to be a secondary hit in the development of B-cell ALL rather than a driving event ³⁶, especially in patients with BCR::ABL1 and IKZF1 deletion. The effects of BCR::ABL1 and IKZF1 deletion on the biological function of ECM1 still need further exploration. Further study of the molecular mechanisms of ECM1 in different genetic backgrounds may provide a more comprehensive understanding of B-cell ALL and promote personalized diagnosis and treatment.

ALL, acute lymphoblastic leukemia; CR, complete remission; ECM1, extracellular matrix protein 1; KMT2A-r, KMT2A rearrangement; MFC, Multi-parameter flow cytometry; MRD, Minimal residual disease; OS, Overall survival; qRT-PCR, quantitative real-time polymerase chain reaction; ROC, receiver operator characteristic

Ethics approval and consent to participate

The study involving human participants was reviewed and approved by the Ethics Committee of Peking University People’s Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Consent for publication

Not applicable

Availability of data and materials

Not applicable

Competing interests

The authors declare that they have no competing of interests.

Funding

This work was supported by grants from the National Key Research and Development Program of China (Grant number 2022YFA1103300), National Natural Science Foundation of China (Grant numbers 81770156, 82100169), Beijing Municipal Natural Science Foundation [Grant 7192213] and the Peking University People’s Hospital Research and Development Funds [Grant number RDF2018-02].

Authors’ Contributions

Guo-Rui Ruan and Xiao-Jun Huang designed the project and supervised the manuscript preparation. Li-Xin Wu, Ming-Yue Zhao, Ya-Lan Zhou and Lei-Ming Cao performed the experiments and statistical analyses. Ya-Zhen Qin, Hao Jiang, Qian Jiang, Lan-Ping Xu, and Xiao-Hui Zhang provided the clinical data. All authors read and approved the final manuscript and agreed to submit for publication.

Acknowledgments

We would like to thank all our colleagues at Peking University Institute of Hematology for their cooperation in sample collection.

Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35(9):975-983.
Tran TH, Langlois S, Meloche C, et al. Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. Blood Adv. 2022;6(4):1329-1341.
Gu Z, Churchman ML, Roberts KG, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296-307.
Studd JB, Cornish AJ, Hoang PH, Law P, Kinnersley B, Houlston R. Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes. Blood Cancer J. 2021;11(11):177.
Wu S, Liu L, Chu X, et al. Dynamic change of variant allele frequency reveals disease status, clonal evolution and survival in pediatric relapsed B-cell acute lymphoblastic leukaemia. Clin Transl Med. 2022;12(5):e892.
Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016;101(4):407-416.
Yang M, Vesterlund M, Siavelis I, et al. Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia. Nat Commun. 2019;10(1):1519.
Mullighan CG. How advanced are we in targeting novel subtypes of ALL? Best Pract Res Clin Haematol. 2019;32(4):101095.
Aldoss I, Afkhami M, Yang D, et al. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023.
Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, et al. Identification of ETV6::RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.
Wang Q, Cai WZ, Wang QR, et al. Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. Am J Hematol. 2023;98(1):66-78.
Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol. 2013;92(8):1111-1119.
Lai YY, Huang XJ, Li J, et al. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China. Leuk Res. 2015;39(5):530-535.
Ruan GR, Qin YZ, Chen SS, et al. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res. 2006;30(9):1159-1165.
Schittek B, Sinnberg T. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Mol Cancer. 2014;13:231.
Dai Z, Cai L, Chen Y, et al. Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1. Front Pharmacol. 2021;12:775680.
Steinhaeuser SS, Morera E, Budkova Z, et al. ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion. Lab Invest. 2020;100(7):928-944.
Bergamaschi A, Tagliabue E, Sørlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357-367.
Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg. 2005;242(3):353-361; discussion 361-353.
Jeong S, Lee SG, Kim H, et al. Simultaneous Expression of Long Non-Coding RNA FAL1 and Extracellular Matrix Protein 1 Defines Tumour Behaviour in Young Patients with Papillary Thyroid Cancer. Cancers (Basel). 2021;13(13):3223.
Xiong GP, Zhang JX, Gu SP, Wu YB, Liu JF. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell. Neoplasma. 2012;59(4):409-415.
Yin H, Jiang Z, Feng X, Ji Z, Jin W. Identification of Sca-1(+)Abcg1(+) bronchioalveolar epithelial cells as the origin of lung adenocarcinoma in Gprc5a-knockout mouse model through the interaction between lung progenitor AT2 and Lgr5 cells. Oncogene. 2020;39(18):3754-3773.
Wang J, Guo M, Zhou X, et al. Angiogenesis related gene expression significantly associated with the prognostic role of an urothelial bladder carcinoma. Transl Androl Urol. 2020;9(5):2200-2210.
Chen H, Jia WD, Li JS, et al. Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma. Med Oncol. 2011;28 Suppl 1:S318-325.
Lv C, Ren C, Yu Y, et al. Wentilactone A Reverses the NF-κB/ECM1 Signaling-Induced Cisplatin Resistance through Inhibition of IKK/IκB in Ovarian Cancer Cells. Nutrients. 2022;14(18).
Long S, Wang J, Weng F, et al. ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction. Front Pharmacol. 2022;13:1005915.
Yu VZ, Ko JMY, Ning L, Dai W, Law S, Lung ML. Endoplasmic reticulum-localized ECM1b suppresses tumor growth and regulates MYC and MTORC1 through modulating MTORC2 activation in esophageal squamous cell carcinoma. Cancer Lett. 2019;461:56-64.
Al Shareef Z, Kardooni H, Murillo-Garzón V, et al. Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1. Oncogene. 2018;37(39):5305-5324.
Zhang J, Sun W, Kong X, et al. Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1. Proc Natl Acad Sci U S A. 2019;116(48):24259-24267.
Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood. 2010;115(23):4657-4663.
Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20(9):1307-1313.
Chen D, Camponeschi A, Wu Q, et al. CD99 expression is strongly associated with clinical outcome in children with B-cell precursor acute lymphoblastic leukaemia. Br J Haematol. 2019;184(3):418-423.
Aguilera-Montilla N, Bailón E, Uceda-Castro R, et al. MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. Oncogene. 2019;38(23):4605-4619.
Zhang Y, Wang W, Zhou H, Cui Y. Urinary Eubacterium sp. CAG:581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway. Cancers (Basel). 2023;15(3).
Fujimoto N, Terlizzi J, Aho S, et al. Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Exp Dermatol. 2006;15(4):300-307.
Irving JA, Enshaei A, Parker CA, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128(7):911-922.

No competing interests reported.

SupplementaryMaterials20230703.docx

Download PDF

Journal Publication

published 28 Mar, 2024

Read the published version in Clinical and Experimental Medicine →

Editorial decision: Revision requested
01 Dec, 2023
Reviews received at journal
06 Nov, 2023
Reviewers agreed at journal
26 Oct, 2023
Reviewers agreed at journal
25 Oct, 2023
Reviewers invited by journal
25 Oct, 2023
Submission checks completed at journal
05 Jul, 2023
Editor assigned by journal
05 Jul, 2023
First submitted to journal
03 Jul, 2023

You are reading this latest preprint version

Extracellular matrix protein 1 (ECM1) is a potential biomarker in B-cell acute lymphoblastic leukemia

Status:

Journal Publication

Version 1

Abstract

Figures

Novelty and Impact

Introduction

Methods

Patients and treatments

Immunophenotype, MRD and cytogenetic analyses

Gene expression microarray

Reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR)

GEO dataset validation

Statistical analysis

Results

Dysregulated gene expression in B-cell ALL

Discussion

Abbreviations

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1